Trend analysis as per recent USFDA guideline [Bioanalytics]

posted by dshah  – India/United Kingdom, 2020-08-01 07:32 (694 d 08:32 ago) – Posting: # 21815
Views: 4,517

Dear All!

If we consider the recent FDA guideline or ICH M10, i believe trend analysis for IS response, CC and QCs is also required. FDA does ask if there is upward or downward trend observed. The important point for SOP of CRO should be - allowed limit for IS response. If this not limited for that 3 subjects, then i believe CRO's practice and SOP needs to be revised.

Regards,
Dshah


Edit: Guidelines linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,170 posts in 4,645 threads, 1,570 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Sunday 16:04 CEST (Europe/Vienna)

The person interested in success has to learn
to view failure as a healthy, inevitable part
of the process of getting to the top.    Joyce Brothers

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5